Metraipolis › archive › dc_a526cd4566a2
CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer — Europe PMC PMID:41375077
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41375077
- DOI
- 10.3390/cancers17233876
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T23:24:33.261Z
- SHA-256 of the archived text
541bb8811a9808117f8e98a6a64cb149d5bec48a941bf58eeb699505d977945c- Stable URL of this page
https://metraipolis.com/documento/dc_a526cd4566a2
How to cite
CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer — Europe PMC PMID:41375077 — Europe PMC (en), https://europepmc.org/article/MED/41375077 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a526cd4566a2 (Metraipolis archive dc_a526cd4566a2, sha256 541bb8811a9808117f8e98a6a64cb149d5bec48a941bf58eeb699505d977945c)
BibTeX
@misc{dca526cd4566a2,
title = {CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer — Europe PMC PMID:41375077},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41375077},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a526cd4566a2; sha256 541bb8811a9808117f8e98a6a64cb149d5bec48a941bf58eeb699505d977945c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41375077. Agents can read the archived copy with the MCP tool read_document.